Logo image of CRGX

CARGO THERAPEUTICS INC (CRGX) Stock Fundamental Analysis

NASDAQ:CRGX - Nasdaq - US14179K1016 - Common Stock - Currency: USD

3.39  -9.8 (-74.3%)

After market: 3.2892 -0.1 (-2.97%)

Fundamental Rating

3

Taking everything into account, CRGX scores 3 out of 10 in our fundamental rating. CRGX was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRGX as it has an excellent financial health rating, but there are worries on the profitability. CRGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRGX had negative earnings in the past year.
CRGX had a negative operating cash flow in the past year.
CRGX Yearly Net Income VS EBIT VS OCF VS FCFCRGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.18%, CRGX is in the better half of the industry, outperforming 63.19% of the companies in the same industry.
CRGX's Return On Equity of -38.45% is fine compared to the rest of the industry. CRGX outperforms 72.92% of its industry peers.
Industry RankSector Rank
ROA -34.18%
ROE -38.45%
ROIC N/A
ROA(3y)-183.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRGX Yearly ROA, ROE, ROICCRGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 1K 2K 3K

1.3 Margins

CRGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRGX Yearly Profit, Operating, Gross MarginsCRGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRGX has more shares outstanding
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRGX Yearly Shares OutstandingCRGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M 40M
CRGX Yearly Total Debt VS Total AssetsCRGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

CRGX has an Altman-Z score of 6.22. This indicates that CRGX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.22, CRGX belongs to the top of the industry, outperforming 82.65% of the companies in the same industry.
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.22
ROIC/WACCN/A
WACCN/A
CRGX Yearly LT Debt VS Equity VS FCFCRGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 18.95 indicates that CRGX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 18.95, CRGX belongs to the top of the industry, outperforming 94.16% of the companies in the same industry.
A Quick Ratio of 18.95 indicates that CRGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 18.95, CRGX belongs to the top of the industry, outperforming 94.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.95
Quick Ratio 18.95
CRGX Yearly Current Assets VS Current LiabilitesCRGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

CRGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -124.71%.
EPS 1Y (TTM)-124.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRGX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.13% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.22%
EPS Next 2Y34.81%
EPS Next 3Y22.17%
EPS Next 5Y14.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRGX Yearly Revenue VS EstimatesCRGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CRGX Yearly EPS VS EstimatesCRGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRGX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRGX Price Earnings VS Forward Price EarningsCRGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRGX Per share dataCRGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as CRGX's earnings are expected to grow with 22.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.81%
EPS Next 3Y22.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARGO THERAPEUTICS INC

NASDAQ:CRGX (1/30/2025, 8:16:07 PM)

After market: 3.2892 -0.1 (-2.97%)

3.39

-9.8 (-74.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners94.97%
Inst Owner Change0.11%
Ins Owners0.24%
Ins Owner Change0%
Market Cap156.04M
Analysts84
Price Target32.49 (858.41%)
Short Float %17.33%
Short Ratio28.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.19%
Min EPS beat(2)2.64%
Max EPS beat(2)23.75%
EPS beat(4)3
Avg EPS beat(4)11.05%
Min EPS beat(4)-1.21%
Max EPS beat(4)23.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.58%
EPS NY rev (1m)0%
EPS NY rev (3m)11.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-4.26
EYN/A
EPS(NY)-4.19
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-2.91
OCFYN/A
SpS0
BVpS8.71
TBVpS8.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.18%
ROE -38.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-183.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 267.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.95
Quick Ratio 18.95
Altman-Z 6.22
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1145.04%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-124.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.14%
EPS Next Y83.22%
EPS Next 2Y34.81%
EPS Next 3Y22.17%
EPS Next 5Y14.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-178.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.78%
EBIT Next 3Y-38.2%
EBIT Next 5YN/A
FCF growth 1Y-181.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-179.2%
OCF growth 3YN/A
OCF growth 5YN/A